Early diagnosis of acute myocardial infarction in patients with mild elevations of cardiac troponin
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28150185
DOI
10.1007/s00392-016-1075-9
PII: 10.1007/s00392-016-1075-9
Knihovny.cz E-zdroje
- Klíčová slova
- Acute myocardial infarction, Copeptin, Diagnosis of AMI,
- MeSH
- biologické markery krev MeSH
- časná diagnóza MeSH
- glykopeptidy krev MeSH
- infarkt myokardu krev diagnóza MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- prospektivní studie MeSH
- ROC křivka MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- troponin I krev MeSH
- troponin T krev MeSH
- urgentní služby nemocnice MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- biologické markery MeSH
- copeptins MeSH Prohlížeč
- glykopeptidy MeSH
- troponin I MeSH
- troponin T MeSH
BACKGROUND: The early diagnosis of acute myocardial infarction (AMI) in patients with mild elevations of high-sensitivity cardiac troponin (hs-cTn) is a challenge. It is unclear whether copeptin, a marker of endogenous stress, or 1h-hs-cTn changes are better suited to address this important unmet clinical need. METHODS: We prospectively enrolled patients presenting with symptoms suggestive of AMI to the emergency department (ED). Two independent cardiologists adjudicated the final diagnosis. Mild hs-cTn elevations were defined as 26.2 ng/L (99th percentile) to 75 ng/L for hs-cTnI, and 14 ng/L (99th percentile) to 50 ng/L (biological-equivalent to 75 ng/L for hs-cTnI) for hs-cTnT. RESULTS: Among 1356 patients, 80 (6%) had mild hs-cTnI elevations at presentation. Within this group, AMI was the final diagnosis in 39 patients (49%). The diagnostic accuracy for the diagnosis of AMI as quantified by the area under the receiver operating characteristic curve (AUC) was 0.51 (95% CI 0.39-0.64) for hs-cTnI at presentation, 0.58 (95% CI 0.45-0.71) for copeptin at presentation, and 0.78 (95% CI 0.68-0.88) for 1h-hs-cTnI changes, which was significantly higher as compared to copeptin (p = 0.02) or hs-cTnI alone (p < 0.001). The additional use of 1h-hs-cTnI changes, but not of copeptin, improved diagnostic accuracy of hs-cTnI at presentation (AUC 0.80, 95% CI 0.70-0.90; p = 0.002 for comparison). Similar findings regarding copeptin and 1h-hs-cTnT/I changes were obtained for mild hs-cTnT elevations. CONCLUSIONS: About 6-22% of patients presenting with suggestive AMI to the ED have mild hs-cTnT/I elevations at presentation. In contrast to copeptin, the addition of 1h-hs-cTn changes substantially improves the early diagnosis of AMI.
2nd Department of Cardiology Medical University of Silesia Zabrze Poland
Blood Transfusion Centre Swiss Red Cross Basel Switzerland
Department of Cardiology University Hospital Brno Brno Czech Republic
Department of Hematology University Hospital Basel Basel Switzerland
Department of Internal Medicine University Hospital Basel University of Basel Basel Switzerland
Emergency Department Hospital Clinic Barcelona Catalonia Spain
Emergency Department University Hospital Zurich Zurich Switzerland
GREAT Network Basel Switzerland
Laboratory Medicine University Hospital Basel Basel Switzerland
Medical Faculty Masaryk University Brno Czech Republic
Servicio de Urgencias Hospital Clínico San Carlos Madrid Spain
Zobrazit více v PubMed
Am J Med. 2015 Apr;128(4):369-79.e4 PubMed
Eur Heart J. 2015 Feb 7;36(6):369-76 PubMed
Eur J Biochem. 1972 Jul 24;28(3):334-9 PubMed
Clin Chem Lab Med. 2012 Feb 03;50(5):871-8 PubMed
Eur Heart J. 2014 Sep 7;35(34):2303-11 PubMed
Eur Heart J Acute Cardiovasc Care. 2016 Sep;5(5):407-15 PubMed
Clin Res Cardiol. 2015 Aug;104(8):679-87 PubMed
Circulation. 2011 Jul 12;124(2):136-45 PubMed
Circulation. 2015 Jun 9;131(23):2032-40 PubMed
Circulation. 2007 Apr 3;115(13):e352-5 PubMed
Clin Res Cardiol. 2014 Apr;103(4):301-13 PubMed
Clin Res Cardiol. 2016 Dec;105(12 ):1030-1041 PubMed
Clin Res Cardiol. 2015 Jan;104(1):71-8 PubMed
Clin Lab. 2011;57(9-10):725-30 PubMed
Eur Heart J. 2007 Oct;28(20):2525-38 PubMed
Clin Chem. 2016 Mar;62(3):494-504 PubMed
BMC Med Inform Decis Mak. 2006 Jul 06;6:28 PubMed
Natl Health Stat Report. 2008 Aug 6;(7):1-38 PubMed
Clin Res Cardiol. 2015 Oct;104(10):803-11 PubMed
N Engl J Med. 2009 Aug 27;361(9):868-77 PubMed
Eur Heart J. 2014 Mar;35(9):552-6 PubMed
Int J Cardiol. 2015;190:170-6 PubMed
N Engl J Med. 2003 Nov 27;349(22):2128-35 PubMed
Clin Res Cardiol. 2015 Feb;104(2):95-111 PubMed
Eur Heart J. 2016 Jan 14;37(3):267-315 PubMed
J Am Coll Cardiol. 2010 May 11;55(19):2096-106 PubMed
Clin Chem. 2012 Nov;58(11):1574-81 PubMed
Clin Chem. 2006 Jan;52(1):112-9 PubMed
Clin Res Cardiol. 2014 Jun;103(6):477-85 PubMed
Clin Res Cardiol. 2014 May;103(5):373-80 PubMed
Am J Cardiol. 2014 May 1;113(9):1581-91 PubMed
Clin Res Cardiol. 2014 Sep;103(9):743-51 PubMed
Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):18-27 PubMed
Am J Med. 2015 Aug;128(8):861-870.e4 PubMed
Biometrics. 1988 Sep;44(3):837-45 PubMed
Int J Cardiol. 2016 Mar 15;207 :238-45 PubMed
Clin Chem. 2010 Feb;56(2):254-61 PubMed
Clin Res Cardiol. 2014 Aug;103(8):655-64 PubMed
Clin Chem Lab Med. 2014 Nov;52(11):1657-65 PubMed
Clin Res Cardiol. 2015 Jul;104(7):566-73 PubMed
Clin Res Cardiol. 2016 Feb;105(2):135-44 PubMed
Am Heart J. 2016 Jan;171(1):92-102.e1-5 PubMed
Eur Heart J. 2012 Sep;33(18):2252-7 PubMed
Arch Intern Med. 2012 Sep 10;172(16):1211-8 PubMed
J Am Coll Cardiol. 2009 Jun 30;54(1):60-8 PubMed
Eur Heart J. 2014 Feb;35(6):365-75 PubMed
Peptides. 2005 Dec;26(12):2500-4 PubMed
N Engl J Med. 2009 Aug 27;361(9):858-67 PubMed
Ann Intern Med. 2006 Aug 15;145(4):247-54 PubMed
Clin Res Cardiol. 2017 Jan;106(1):49-57 PubMed